Cancer drug shows strong activity against SARS-CoV-2 in lab studies
Updated Jan 29, 2021;
Posted Jan 29, 2021
FILE - This 2020 electron microscope image provided by the National Institute of Allergy and Infectious Diseases - Rocky Mountain Laboratories shows SARS-CoV-2 virus particles which cause COVID-19, isolated from a patient in the U.S., emerging from the surface of cells cultured in a lab. Viruses are constantly mutating, with coronavirus variants circulating around the globe. (NIAID-RML via AP)AP
Facebook Share
A report released on Jan. 25 by the University of California San Francisco, revealed that scientists at UC San Francisco’s Quantitative Bioscience Institute (QBI) and the Icahn School of Medicine at Mt. Sinai (ISMMS) in New York, have found that “a drug approved by the Australian Regulatory Agency for the treatment of multiple myeloma, has potent antiviral activity against SARS-CoV-2 - the virus that causes COVID-19.”